Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shaozhang Zhou, Huilin Wang, Wei Jiang & Qitao Yu. (2019) Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation. OncoTargets and Therapy 12, pages 8863-8871.
Read now
Read now
Marco Tagliamento, Carlo Genova, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Angela Alama, Simona Coco, Simona Boccardo & Francesco Grossi. (2018) Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opinion on Pharmacotherapy 19:18, pages 2055-2062.
Read now
Read now
Articles from other publishers (31)
Elliott Brea & Julia Rotow. (2023) Targeted Therapy for Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America 37:3, pages 575-594.
Crossref
Crossref
Lei Pan, Fanqi Meng, Wei Wang, Xu-hao Wang, Hui Shen, Pengchen Bao, Jian Kang & Delei Kong. (2023) Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Frontiers in Immunology 13.
Crossref
Crossref
Sosuke Matsumura, Satoshi Ano, Norihiro Kikuchi, Michiko Masuda, Hajime Osawa, Yuzuru Kondo, Yukio Ishii & Nobuyuki Hizawa. (2023) A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma. SAGE Open Medical Case Reports 11, pages 2050313X2311595.
Crossref
Crossref
Stephanie Tuminello, Naomi Alpert, Rajwanth R. Veluswamy, Arvind Kumar, Jorge E. Gomez, Raja Flores & Emanuela Taioli. (2022) Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis. BMC Cancer 22:1.
Crossref
Crossref
Nguyen Van Hiep, Wei-Lun Sun, Po-Hao Feng, Cheng-Wei Lin, Kuan-Yuan Chen, Ching-Shan Luo, Le Ngoc Dung, Hoang Van Quyet, Sheng-Ming Wu & Kang-Yun Lee. (2022) Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma. Frontiers in Oncology 12.
Crossref
Crossref
Sally C.M. Lau, Yuanwang Pan, Vamsidhar Velcheti & Kwok Kin Wong. (2022) Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell 40:11, pages 1279-1293.
Crossref
Crossref
Wei-Chun Lin, Wang-Ming Chen, Mingchih Chen, Ben-Chang Shia & Szu-Yuan Wu. (2022) Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA–IIIB Squamous Cell Carcinoma of the Lungs. Clinical Nuclear Medicine 47:8, pages 677-683.
Crossref
Crossref
Anna Michelotti, Marco de Scordilli, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte & Alessandra Bearz. (2022) NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. International Journal of Molecular Sciences 23:12, pages 6748.
Crossref
Crossref
Anna Rekowska, Piotr Rola, Magdalena Wójcik-Superczyńska, Izabela Chmielewska, Paweł Krawczyk & Janusz Milanowski. (2022) Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review. Current Oncology 29:5, pages 3531-3539.
Crossref
Crossref
Matthew Lee, Dhruv Patel, Sebastian Jofre, Shabnam Fidvi, Mark Suhrland, Perry Cohen & Haiying Cheng. (2022) Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review. Clinical Lung Cancer 23:3, pages e276-e282.
Crossref
Crossref
Jialin Qu, Li Wang, Man Jiang, Zhimin Wei, Guangming Fu & Xiaochun Zhang. (2021) Survival-associated N6-adenosine methyltransferase signatures in lung squamous cell carcinoma and clinical verification. BMC Cancer 21:1.
Crossref
Crossref
Nathaniel Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou & Rami Manochakian. (2021) Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Farastuk Bozorgmehr, Daniel Kazdal, Inn Chung, Martina Kirchner, Nikolaus Magios, Mark Kriegsmann, Michael Allgäuer, Laura V. Klotz, Thomas Muley, Rami A. El Shafie, Jürgen R. Fischer, Martin Faehling, Albrecht Stenzinger, Michael Thomas & Petros Christopoulos. (2021) De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Qing Chang, Huiping Qiang, Jialin Qian, Yuqiong Lei, Jiahuan Lu, Hui Feng, Yiming Zhao, Baohui Han, Yanwei Zhang & Tianqing Chu. (2021) Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. Frontiers in Oncology 11.
Crossref
Crossref
Seung Hyeun Lee, Cheol‐Kyu Park, Sung Yong Lee & Chang‐Min Choi. (2021)
Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (
SPACE
study)
. Thoracic Cancer 12:8, pages 1264-1268.
Crossref
Crossref
Hae-Yun Jung, Tae Ho Kim, Jong-Eun Lee, Hong Kwan Kim, Jong Ho Cho, Yong Soo Choi, Sumin Shin, Se-Hoon Lee, Hwanseok Rhee, Hee Kyung Lee, Hyun Jung Choi, Hye Yoon Jang, Seungjae Lee, Jung Hee Kang, Young Ae Choi, Sanghyuk Lee, Jinseon Lee, Yoon La Choi & Jhingook Kim. (2020) PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications. Journal of Translational Medicine 18:1.
Crossref
Crossref
P. Christopoulos, M. Kirchner, J. Roeper, F. Saalfeld, M. Janning, F. Bozorgmehr, N. Magios, D. Kazdal, A.L. Volckmar, L.M. Brückner, T. Bochtler, M. Kriegsmann, V. Endris, R. Penzel, K. Kriegsmann, M. Eichhorn, F.J.F. Herth, C.P. Heussel, R.A. El Shafie, M.A. Schneider, T. Muley, M. Meister, M. Faehling, J.R. Fischer, L. Heukamp, P. Schirmacher, H. Bischoff, M. Wermke, S. Loges, F. Griesinger, A. Stenzinger & M. Thomas. (2020) Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 148, pages 105-112.
Crossref
Crossref
MuYun Peng, QiuYuan Wen, Xia Wu, FengLei Yu & WenLiang Liu. (2020)
Osimertinib for compound
EGFR
exon 19 deletion/T790M mutated lung squamous cell carcinoma
. Thoracic Cancer 11:9, pages 2704-2708.
Crossref
Crossref
Saurabh Zanwar. (2020) Epidermal growth factor receptor mutated lung cancers: Looking beyond adenocarcinomas. Indian Journal of Cancer 0:0, pages 0.
Crossref
Crossref
Momin T. Siddiqui, Fernando Schmitt & Andrew Churg. (2019) Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma. Journal of the American Society of Cytopathology 8:6, pages 352-361.
Crossref
Crossref
Kanakasetty Babu Govind, Deepak Koppaka, Lokanatha Dasappa, Linu Abraham Jacob, Suresh M.C. Babu, N. Kadabur Lokesh, Rudresha Antapura Haleshappa, L.K. Rajeev, Smitha Carol Saldanha, Anand Abhishek, Vikas Asati, R. Chethan & Vedam Laxmi Ramprasad. (2020) Detection of clinically relevant epidermal growth factor receptor pathway mutations in circulating cell-free tumor DNA using next generation sequencing in squamous cell carcinoma lung. South Asian Journal of Cancer 08:04, pages 247-249.
Crossref
Crossref
Sehhoon Park, Joon Ho Shim, Boram Lee, Inju Cho, Woong-Yang Park, Youjin Kim, Se-Hoon Lee, Yoon La Choi, Joungho Han, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park & Jong-Mu Sun. (2019) Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. Lung Cancer 134, pages 7-15.
Crossref
Crossref
Danilo Rocco, Ciro Battiloro, Luigi Della Gravara & Cesare Gridelli. (2019) Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. Reviews on Recent Clinical Trials 14:2, pages 120-128.
Crossref
Crossref
Kumar Prabhash, Suresh H. Advani, Ullas Batra, Bivas Biswas, Anuradha Chougule, Mithua Ghosh, Vamshi Krishna Muddu, T. P. Sahoo & Ashok K. Vaid. (2019) Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing. Advances in Therapy 36:4, pages 766-785.
Crossref
Crossref
Maike Wittersheim, Simon Schallenberg & Reinhard Büttner. (2019) Nichtkleinzelliges Lungenkarzinom – Pathologie und BiologieNon-small cell lung cancer—pathology and biology. Wiener klinisches Magazin 22:2, pages 60-67.
Crossref
Crossref
Ruixia Qi, Fengyun Dong, Qiang Liu, Yoshiki Murakumo & Ju Liu. (2018) CD109 and squamous cell carcinoma. Journal of Translational Medicine 16:1.
Crossref
Crossref
Maike Wittersheim, S. Schallenberg & R. Büttner. (2018) Nichtkleinzelliges Lungenkarzinom – Pathologie und BiologieNon-small cell lung cancer—pathology and biology. Der Onkologe 24:12, pages 958-966.
Crossref
Crossref
Alain C. Borczuk. (2018) Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. Archives of Pathology & Laboratory Medicine 142:8, pages 914-921.
Crossref
Crossref
Venus Sosa Iglesias, Lorena Giuranno, Ludwig J. Dubois, Jan Theys & Marc Vooijs. (2018) Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?. Frontiers in Oncology 8.
Crossref
Crossref
Yuri Taniguchi, Yoko Matsumoto, Ryutaro Furukawa, Sayaka Ohara & Kazuhiro Usui. (2018) The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. International Journal of Clinical Oncology 23:3, pages 452-457.
Crossref
Crossref
Fumika Hirabayashi, Kenjiro Iwanaga, Toshinori Okinaga, Osamu Takahashi, Wataru Ariyoshi, Ryo Suzuki, Mutsumi Sugii, Kazuo Maruyama, Kazuhiro Tominaga & Tatsuji Nishihara. (2017) Epidermal growth factor receptor-targeted sonoporation with microbubbles enhances therapeutic efficacy in a squamous cell carcinoma model. PLOS ONE 12:9, pages e0185293.
Crossref
Crossref